| Stereochemistry | ACHIRAL |
| Molecular Formula | C15H13ClNO3.Na.2H2O |
| Molecular Weight | 349.742 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.[Na+].CN1C(CC([O-])=O)=CC(C)=C1C(=O)C2=CC=C(Cl)C=C2
InChI
InChIKey=ZJXLSCXDGPDZOL-UHFFFAOYSA-M
InChI=1S/C15H14ClNO3.Na.2H2O/c1-9-7-12(8-13(18)19)17(2)14(9)15(20)10-3-5-11(16)6-4-10;;;/h3-7H,8H2,1-2H3,(H,18,19);;2*1H2/q;+1;;/p-1
Zomepirac Sodium (Zomax) is a pyrrole-acetic acid structurally related to tolmetin sodium. Zomepirac is a prostaglandin synthetase inhibitor and is not an opioid, an opioid antagonist, or a salicylate. Zomepirac was approved by the Food and Drug Administration for marketing in the United States as an analgesic. It was indicated for all forms of mild to moderately severe pain, and was being promoted as a "comprehensive, non-addicting analgesic." Later Zomepirac was found to be associated with fatal and near-fatal anaphylactoid reactions. The manufacturer voluntarily removed Zomax tablets from the Canadian, US, and UK markets in March 1983.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 15.0 µM [IC50] |
Doses
AEs
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
Drug as victim
Sourcing
PubMed
Patents
Sample Use Guides
The oral dose of zomepirac for mild to moderately
severe pain is 50-100 mg every four to six hours. In
acute moderate to severe pain in adults, a 100-mg
dose would be reasonable initial therapy. In chronic
pain situations, the 50-mg dose may be as effective in
some patients as the 100-mg dose. Doses of more
than 100 mg are not recommended.
Route of Administration:
Oral
Zomepirac failed to displace tritiated etorphine significantly at concentrations up to 200 umol/l. It was active (3-7 X 10(-5) mol/l) on both the electrically stimulated guinea pig ileum and mouse vas deferens but was less efficacious than morphine; these effects were not reversed by narcotic antagonists.
ACTIVE MOIETY
SUBSTANCE RECORD
